Growth hormone therapy in achondroplasia

Abstract excerpt

A pilot study was carried out to examine the safety and efficacy of recombinant human growth hormone for growth-promoting therapy of achondroplasia. The data suggest that the agent in doses used to treat non-GH-deficient forms of short stature (0.3 mg/kg/wk) modestly increases overall height velocity in some children with achondroplasia. The effect was seen mainly in children with the lowest growth velocities...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Connective tissue disorders research
• Share to Growth Hormone and Insulin-like Growth Factors
• Share to Hip disorders and treatments